Lipoatrophy: a non–reversible complication of subcutaneous interferon–beta 1a treatment of multiple sclerosis

Beiske, Antonie Giæver; Myhr, Kjell–Morten

doi:10.1007/s00415-006-0898-0

Cited by 12 publications

(12 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In some of these cases, lipoatrophy persisted or continued to enlarge despite cessation of GA. 58,59 There were two documented cases published in which lipoatrophy was associated with SC IFN-β-1a and IFN-β-1b, respectively. 60,61 Some case reports reported a combination of panniculitis and lipoatrophy in association with GA or with IFN-β-1b. 57,60,62 Cutaneous ulcers and necrosis Cutaneous ulcers were mainly described in patients who were treated with IFN-β-1b.…”

Section: Lipoatrophymentioning

confidence: 99%

“…60,61 Some case reports reported a combination of panniculitis and lipoatrophy in association with GA or with IFN-β-1b. 57,60,62 Cutaneous ulcers and necrosis Cutaneous ulcers were mainly described in patients who were treated with IFN-β-1b. A study by Webster and colleagues reported 8 (2%) out of 400 patients treated with IFN-β-1b who had developed skin ulcers.…”

Section: Lipoatrophymentioning

confidence: 99%

See 1 more Smart Citation

Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic review

et al. 2012

View full text Add to dashboard Cite

Glatiramer acetate and interferon-beta are approved first-line disease-modifying treatments (DMTs) for multiple sclerosis (MS). DMTs can be associated with cutaneous adverse events, which may influence treatment adherence and patient quality of life. In this systematic review, we aimed to provide an overview of the clinical spectrum and the incidence of skin reactions associated with DMTs. A systematic literature search was performed up to May 2011 in Medline, Embase, and Cochrane databases without applying restrictions in study design, language, or publishing date. Eligible for inclusion were articles describing any skin reaction related to DMTs in MS patients. Selection of articles and data extraction were performed by two authors independently. One hundred and six articles were included, of which 41 (39%) were randomized controlled trials or cohort studies reporting incidences of mainly local injection-site reactions. A large number of patients had experienced some form of localized injection-site reaction: up to 90% for those using subcutaneous formulations and up to 33% for those using an intramuscular formulation. Sixty-five case-reports involving 106 MS patients described a wide spectrum of cutaneous adverse events, the most frequently reported being lipoatrophy, cutaneous necrosis and ulcers, and various immune-mediated inflammatory skin diseases. DMTs for MS are frequently associated with local injection-site reactions and a wide spectrum of generalized cutaneous adverse events, in particular, the subcutaneous formulations. Although some of the skin reactions may be severe and persistent, most of them are mild and do not require cessation of DMT.

show abstract

Section: Lipoatrophymentioning

confidence: 99%

Section: Lipoatrophymentioning

confidence: 99%

Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic review

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Although glatiramer acetate has been associated with lipoatrophy, only one recent report describes non-reversible lipoatrophy occurring in a patient with multiple sclerosis during IFNb-1a treatment. 4 Buttmann et al 5 chemokine expression by induction of proinflammatory cytokines. This study showed a strong chemokine IP-10/CXCL10 expression associated with extensive perivascular T cell and macrophage infiltrates at the injection sites of IFNb-1a.…”

mentioning

confidence: 99%

Panniculitis and lipoatrophy after subcutaneous injection of interferon -1b in a patient with multiple sclerosis

O'Sullivan¹,

Cronin

Sweeney

et al. 2006

Journal of Neurology, Neurosurgery & Psychiatry

View full text Add to dashboard Cite

“…Only two cases have been reported in the literature: one in a patient treated with IFNβ-1a 22 µg SC TIW and the other with IFNβ-1b SC QOD. 23,25 Lipoatrophy is more commonly associated with use of glatiramer acetate. A chart review found 45% (34 of 76) of glatiramer acetate-treated patients experiencing lipoatrophy, with severe lipoatrophy reported in 15% (5) of those cases.…”

Section: Disease-modifying Therapies Ifnβ β and Glatiramer Acetatementioning

confidence: 99%

“…[23][24][25][26] Lipoatrophy is a rare complication in patients treated with IFNβ. Only two cases have been reported in the literature: one in a patient treated with IFNβ-1a 22 µg SC TIW and the other with IFNβ-1b SC QOD.…”

Section: Disease-modifying Therapies Ifnβ β and Glatiramer Acetatementioning

confidence: 99%

Review: Optimizing Adherence to Multiple Sclerosis Therapies

B¹,

Lucas²,

Kresa-Reahl³

et al. 2008

International Journal of MS Care

View full text Add to dashboard Cite

Disease-modifying drugs (DMDs) have transformed the treatment of relapsing-remitting multiple sclerosis (RRMS). Several studies have shown the benefits of long-term treatment in RRMS; however, all multiple sclerosis (MS) therapies are associated with treatment-related tolerability and safety issues that may challenge patient compliance with therapy. Tolerability issues include flulike symptoms and injection-site reactions for interferon β(IFNβ) and lipoatrophy and systemic postinjection reactions for glatiramer acetate (GA). Altered blood cell counts, depression, and elevated liver enzymes, including rare cases of acute liver injury, are safety issues that have been associated with IFNβand, rarely, systemic anaphylactoid reactions with glatiramer acetate. Common tolerability issues associated with natalizumab are hypersensitivity and postinfusion reactions, and mitoxantrone may cause amenorrhea, nausea, and alopecia. Serious safety issues that have limited the use of natalizumab and mitoxantrone as first-line treatments are progressive multifocal leukoencephalopathy for natalizumab and cardiotoxicity and leukemia for mitoxantrone. Although both tolerability and safety issues can affect patient adherence to therapy, numerous strategies are available to manage tolerability and monitor safety issues. Through careful monitoring of treatment-related safety issues, patient education, and tolerability management strategies, treatment nonadherence can be minimized, thereby maximizing the treatment benefits of DMDs.

show abstract

Lipoatrophy: a non–reversible complication of subcutaneous interferon–beta 1a treatment of multiple sclerosis

Cited by 12 publications

References 8 publications

Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic review

Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic review

Panniculitis and lipoatrophy after subcutaneous injection of interferon -1b in a patient with multiple sclerosis

Review: Optimizing Adherence to Multiple Sclerosis Therapies

Contact Info

Product

Resources

About